Mylotarg
information and resources from the National Cancer Institute
Mylotarg
(Other name for: gemtuzumab ozogamicin)
gemtuzumab ozogamicin
Accel. Approv. (clinical benefit not established) Treatment of CD33 positive acute myeloid leukemia in patients in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy.
Wyeth Ayerst May 17 2000
|
|
|
|
news articles
Coming boom in cancer drugs. Nov 7, 2005
CNN Mylotarg, from Wyeth Pharmaceuticals (down $0.18 to $44.82, Research), for the treatment of a specific type of relapsed leukemia in patients 60 or older who ...
PDL Announces Third Quarter 2005 Financial Results Nov 1, 2005
PR Newswire (press release), ...antibody humanization patents: Avastin(TM), Herceptin(R), Xolair(R) and Raptiva(R) from Genentech, Inc.; Synagis(R) from MedImmune, Inc.; Mylotarg(R) from ...
Submitted Data Confirms Doxil Clinical Benefit, J&J Maintains In ... Nov 7, 2005
FDA Advisory Committee ...to Doxil, the committee will review Genzyme’s Campath, Pfizer’s Celebrex, SkyePharma’s DepoCyt, MedImmune’s Ethyol, Wyeth’s Mylotarg and Seragen’s ...
OXFORD BIOMEDICA PLC ANNOUNCES WYETH PRECLINICAL DATA Oct 18, 2005
Market Wire (press release) Wyeth has successfully demonstrated the concept of antibody-targeted chemotherapy through the development and registration of its product Mylotarg(R), which ...
|
|
